Meet the maker: EPM talks to CN Bio’s Jean-Pierre Joubert – EPM Magazine

EPM speaks to Jean-Pierre Joubert, product manager at CN Bio Innovations who talks about his journey into biotech, the challenges of drug development, and why opportunities come from unlikely places.Could you give us a brief description of yourself and what you do at CN Bio?

Coming from a microbiology and biochemistry background, with a diverse array of interesting past roles, I have a unique perspective and approach in what I do. My previous roles include genomics product manager for a large multinational company, marketing manager, product manager for a microbiological biotechnology start-up, overseeing customer relations and sales, as well as being the laboratory manager for one of the largest aquariums in the southern hemisphere!

As a product manager at CN Bio Innovations, a market-leading organ-on-chip biotech company, I am tasked with ensuring the successful launch of my product, managing the lifecycle to ascertain a driving position within the global drug development market.

Teamwork. Intriguing.Dynamic. Coordination. Research.

Upon moving to the UK from South Africa in 2016, where I was a laboratory manager in a large public aquarium, I entered the biotech field. My first product manager role was launching market-disruptive equipment related to microbiological testing (perfect with my background in microbiology and biochemistry). This linked very closely with the pharma market, and subsequent roles kept this association as a genomics product manager and now as a product manager at CN Bio Innovations, working with equipment centred within the pharma and biotechnology spectrum.

It is going to sound clichd, but every time I bring a new product to market, it is a new career highlight. Being a product ,manager means being involved in every aspect of the product development from inception to launch (and beyond). Seeing something which is a culmination of ideas, proposals, design modifications and user feedback is really a fulfilling experience. I am in the fortunate position of managing products which I truly believe will make a difference making it easy to be passionate about them!

I tend to get involved too easily, agreeing to take on more and more. I think that is why product management suits me so well I am able to be involved in many different facets of the product cycle, though I have had to train myself to delegate and not keep putting my hand up, but rather guide others where needed.

There is so much! I love being involved in bringing new technology, which I really believe will make a difference, to market. Working with diverse teams I get to learn something new every day, which is very important to me and keeps me growing. Being customer-facing is a huge boon to me. I absolutely love interacting with customers and building new relationships the interplay can be quite exhilarating.

And my team at CN Bio (of course). Our company is very close-knit, filled with people at the top of their field working together as a cohesive, caring and informal team!

The one thing I would change is accessibility to market. Organ-on-chip and microfluidic technology is still very unknown, which makes market penetration quite challenging. Though we are making a difference within the industry, I do feel that getting the technology out there and increasing exposure would benefit everyone on all levels of the industry ladder!

Outside of product management, I really enjoy marketing. Having done quite a bit of it throughout my career, it is my second passion.

Resource optimisation. In this time of remote working I think people are going to need to optimise resources such as staff, space and other resources. Combine this with a greater need for medical research and drug development at a greater pace, and you have quite a challenging environment on the horizon. But it is also an exciting frontier which leaves a lot of space for innovation which is why we at CN Bio are constantly working to improve, innovate and push the envelope.

If the Covid-19 crisis has shown us anything, it is that there are opportunities in the most unlikely places.

I think major opportunities lie in drug development and redevelopment. Being able to increase drug development efficiency, to optimise current models or test existing compounds for new applications is the wave that is building hard and fast. The pandemic has also seen companies open more to collaborations, which I feel will be the cornerstone that facilitates the greatest breakthroughs.

We at CN Bio Innovations are already collaborating with a wide variety of partners on this front from academics to some of the worlds biggest pharma companies and regulatory bodies. Being able to bring health solutions to market cheaper and faster benefits the whole world, empowering us all to achieve our full potential.

Original post:
Meet the maker: EPM talks to CN Bio's Jean-Pierre Joubert - EPM Magazine

Biochemistry Analyser Market Registered 5.5% CAGR with the Market Value US$ 4700 Mn in Forecast Year 2024 – WaterCloud News

New York City, United States With the outbreak of COVID-19 in worldwide and stipulated lockdown, the healthcare sector is witnessing an unprecedented slowdown as per EY-FICCI study titled, COVID-19 impact assessment for healthcare sector and key financial measures recommendations for the sector. The study is predicated on an assessment of healthcare players within the country to assess the economic impact of the COVID-19 pandemic and provides recommendations on the fiscal stimulus measures it needs within the coming months.

The clinical use of biochemistry analyzers in measurement solutions such as latex agglutination, ion-selective potentiometry, and colorimetric & photometric testing. In addition to this, accuracy of biochemistry analyzers in analyzing blood and urine samples has benefited pathology labs and diagnostic centers across the globe. Persistence Market Research predicts that the global demand for biochemistry analyzers will continue to soar on the grounds of such factors.

A recent report published by Persistence Market Research projects that by the end of 2024, the global market for biochemistry analyzers will reach US$ 4,625.3 Mn in terms of value.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/6451

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/6451

Key findings in the report cite that the use of chemistry analyzers spans from high-throughput clinical labs to point-of-care clinics, and its use for testing enzymes, electrolytes and proteins is gaining traction.

The report current values the globalbiochemistry analyzer marketat a little over US$ 3,000 Mn. During the forecast period, revenues generated through global sales of biochemistry analyzers are, thus, expected to soar at a steady CAGR of 5.5%.

Key Research Insights from the Report include:

The global market for biochemistry analyzers represents absolute $ opportunity of US$ 154.6 Mn in 2017 over 2016 and incremental opportunity of US$ 1,570.8 Mn between 2016 and 2024

Apart from clinical diagnostics, critical applications of biochemistry analyzers include drugs-of-abuse testing and diagnostic testing of patients metabolic functions

Access Full Report @ https://www.persistencemarketresearch.com/checkout/6451

Over 40% of biochemistry analyzers sold across the globe during the forecast period will be concentrated in North America

Demand for biochemistry analyzers is also expected to surge in Asia-Pacific, revenues from which will record steadfast growth at 6.1% CAGR

Leading manufacturers of biochemistry analyzers are developing multiplexing analyzers a cost-effective upgrade to existing product line

The report further reveals that fully-automated biochemistry analyzers will remain in great demand in the years to come. In 2017 and beyond, more than 85% of global biochemistry analyzer revenues will be accounted by sales of fully-automated biochemistry analyzers.

Moreover, clinical diagnostics will also remain the largest application of biochemistry analyzers throughout the forecast period. Revenues accounted by global sales of biochemistry analyzers in clinical diagnostics are anticipated to register speedy growth at 5.7% CAGR.

The report further identifies diagnostic centers as largest end-users of biochemistry analyzers in the world. On the other hand, rising number of point-of-care diagnostic labs instated in hospitals will render a key end-user of biochemistry analyzers. Together, hospitals and diagnostics centers will be responsible for procure over two-third of global biochemistry analyzers revenues through 2024.

More here:
Biochemistry Analyser Market Registered 5.5% CAGR with the Market Value US$ 4700 Mn in Forecast Year 2024 - WaterCloud News

Rowan junior named a top undergrad researcher in chemistry – Rowan Today

A Rowan University student has received the prestigious Eastern Analytical Symposium Undergraduate Student Research Award for 2020.

Joshua Davis, from Swedesboro, New Jersey, is one of four students nationally recognized for their work in the field of analytical chemistry. Awardees are selected by an independent jury of experts from nominations received from the scientific community at large.

Davis was nominated and selected for his outstanding work developing novel microfluidic devices designed for both point-of-care clinical diagnostics and fundamental studies related to breast cancer metastasis. His efforts have been partially supported through a Restek Academic Support Program grant.

The award selection committee also appreciated Daviss efforts during the COVID-19 pandemic. This spring, he was part of a collaborative team of Rowan University faculty and students that created 3D-printed face masks to address a shortage of personal protective equipment for South Jerseys health care workers and emergency responders.

Davis will receive an honorarium, travel expenses to the November 2020 Eastern Analytical Symposium in Princeton, a plaque, and the opportunity to present his work at the symposium.

Rowan University President Dr. Ali Houshmand praised the College of Science & Mathematics for preparing Davis.

This is truly impressive and a testament to the high level of undergraduate research that takes place in the College, Houshmand said. Congratulations to Josh and the entire Chemistry faculty.

"For two years in a row, the Eastern Analytical Symposium has recognized a Rowan University undergraduate for research excellence, said Dr. Beena Sukumaran, Rowans vice president of research. We are so gratified to know that our students' hard work and dedication in the lab are earning the respect they deserve. Joshua Davis award exemplifies what we value at Rowan, which is the integration of undergraduate students in research."

For the past two years, Davis has been working in the laboratory of Dr. James Grinias, assistant professor in the Department of Chemistry & Biochemistry. His research focuses on how to reduce the size and cost of pumping mechanisms for analytical devices.

Traditional devices are still very large and require samples to be taken in the lab. Davis believes his research on reducing the size of microfluidic devices is important, because it enables chemical and biological analytical costs to be reduced while obtaining results similar to those found with benchtop equipment.

The thing that makes Josh special is his strong work ethic and his relentless dedication to excellence, Grinias said. He works so hard to finish just one more experiment to really make sure that his new microfluidic devices are working properly or to confirm that the data truly answers the questions he is asking.

Davis values the opportunity to do laboratory work as an undergraduate.

To do undergraduate research, in my eyes, is very important because it bridges the gap from fundamentals learned in the classroom to the application of what is being studied, Davis said. It allows you to gain the experience that you will need to solve problems in a job setting or in graduate school.

In turn, Grinias values Davis contributions in the lab.

He is technically gifted and has taught himself many engineering-related skills that we need for our research, that I myself did not possess, said Grinias. His ultimate goal is the success of the project and he will not rest until he achieves it.

In addition to this honor, Davis was named Rowan Universitys Department of Chemistry & Biochemistry winner of the American Chemical Society Undergraduate Award in Analytical Chemistry for 2020.

Davis plans to continue his research during his upcoming senior year at Rowan. After graduation, he plans to pursue graduate studies in analytical chemistry.

His true goal in the pursuit of a career in analytical chemistry is to help others, a trait I truly admire in him, said Grinias.

Davis is the second student from Rowan University to receive this award. Samuel Foster, also a member of the Grinias lab team, won the award in 2019. Foster graduated with a B.S. in Chemistry in May 2020 and will begin his graduate studies in analytical chemistry this fall at Rowan University.

The rest is here:
Rowan junior named a top undergrad researcher in chemistry - Rowan Today

Join Michael Behe for an Online Conversation about Viruses and Evolution – Discovery Institute

In a free online Zoom webinar on Saturday, June 13, biochemist Behe will review the biochemistry of viruses in general and COVID-19 in particular. He will use these topical examples to illustrate a fundamental principle: Darwinian and other unintelligent evolutionary mechanisms can change life marginally, in ways that are medically important, yet they cannot explain lifes complex structure. Rather, the elegant molecular structures of life required purposeful intelligent design.

Join us from 6 pm to 7:30 pm. Registration is required! Find more information and a link to register here. The event is graciously sponsored by the Colorado, Houston, and Southern California ChaptersofDiscovery Institutes Science & Culture Network.

Photo credit: Michael Behe, by Chris Morgan.

See the article here:
Join Michael Behe for an Online Conversation about Viruses and Evolution - Discovery Institute

[PDF] Essential Cell Biology Download Full PDF Book Download

Bruce Alberts,Dennis Bray,Karen Hopkin,Alexander D Johnson,Julian Lewis,Martin Raff,Keith Roberts,Peter Walter 2013-10-15Science

Bruce Alberts,Dennis Bray,Alexander Johnson,Julian Lewis,Peter Walter,Martin Raff,Keith Roberts 1998Science

Bruce Alberts,Karen Hopkin,Alexander D. Johnson,Martin Raff,David Morgan,Keith Roberts,Peter Walter 2018-11-19Science

Alberts,Bruce,Hopkin, Karen,Johnson, Alexander D.,Morgan, David,Raff, Martin,Roberts, Keith,Walter, Peter 2018-11-19Science

Fifth International Student Edition

Bruce Alberts,Dennis Bray,Karen Hopkin,Julian Lewis,Alexander D. Johnson,Martin Raff,Keith Roberts,Peter Walter 2016-06-01

N.A 1997Biochemistry

An Introduction to the Molecular Biology of the Cell

John Davey,Mike Lord,J. Michael Lord 2003-06-05Science

Cell Structure

John Davey,J. Mike Lord 2003Cytology

Excerpt from:
[PDF] Essential Cell Biology Download Full PDF Book Download

Texas A&M Researchers Use 3D-Printed Biomaterials Laced With Stem Cells To Create Superior Bone Grafts – Texas A&M University Today

NICE ink developed by Texas A&M researchers can be used to 3D print customizable craniofacial implants.

Courtesy of Akhilesh Gaharwar

Subtle variations in the architecture of the 22 bones of the skull give each one of us a unique facial profile. So repairing the shape of skull defects, in the event of a fracture or a congenital deformity, calls for a technique that can be tailored to an individuals face or head structure.

In a new study, researchers at Texas A&M University have combined 3D printing, biomaterial engineering and stem cell biology to create superior, personalized bone grafts. When implanted at the site of repair, the researchers said these grafts will not only facilitate bone cells to regrow vigorously, but also serve as a sturdy platform for bone regeneration in a desired, custom shape.

Materials used for craniofacial bone implants are either biologically inactive and extremely hard, like titanium, or biologically active and too soft, like biopolymers, said Roland Kaunas, associate professor in the Department of Biomedical Engineering. In our study, we have developed a synthetic polymer that is both bioactive and mechanically strong. These materials are also 3D printable, allowing custom-shaped craniofacial implants to be made that are both aesthetically pleasing and functional.

A detailed report on the findings was published online in the journalAdvanced Healthcare Materialsin March.

Each year, about 200,000 injuries occur to bones of the jaw, face and head. For repair, physicians often hold these broken bones in place using titanium plates and screws so that surrounding bone cells can grow and form a cover around the metal implant. Despite its overall success in aiding bone repair, one of the major drawbacks of titanium is that it does not always integrate into bone tissue, which can then cause the implant to fail, requiring another surgery in advanced cases.

Thus, biocompatible polymers, particularly a type called hydrogels, offer a preferable alternative to metal implants. These squishy materials can be loaded with bone stems cells and then 3D printed to any desired shape. Also, unlike titanium plates, the body can degrade hydrogels over time. However, hydrogels also have a known weakness.

Although the pliability of hydrogel-based materials makes them good inks for 3D bioprinting, their softness compromises the mechanical integrity of the implant and the accuracy of printed parts, said Akhilesh Gaharwar, associate professor in the Department of Biomedical Engineering.

To increase the stiffness of the hydrogel, the researchers developed a nanoengineered ionic-covalent entanglement or NICE recipe containing just three main ingredients: an extract from seaweed called kappa carrageenan, gelatin and nanosilicate particles that both stimulate bone growth and mechanically reinforce the NICE hydrogel.

First, they uniformly mixed the gelatin and kappa carrageenan at microscopic scales and then added the nanosilicates. Gaharwar said the chemical bonds between these three items created a much stiffer hydrogel for 3D bioprinting with an almost eight-fold increase in strength compared to individual components of NICE bioink.

Next, they added adult stem cells to 3D parts printed with NICE ink and then chemically induced the stem cells to convert into bone cells. Within a couple of weeks, the researchers found that the cells had grown in numbers, producing high levels of bone-associated proteins, minerals and other molecules. In aggregate, these cell secretions formed a scaffold, known as an extracellular matrix, with a unique composition of biological materials needed for the growth and survival of developing bone cells.

When the scaffolds are fully developed, the researchers noted that the bone cells could be removed from the scaffold and the hydrogel-based implant can then be inserted into the site of skull injury where the surrounding, healthy bones initiate healing.Over time, the 3D printed scaffolds biodegrade, leaving behind a healed bone in the right shape.

The idea is to have the bodys own bone repair machinery participate in the repair process, Kaunas said. Our biomaterial is enriched with this regenerative extracellular matrix, providing a fertile environment to naturally trigger bone and tissue restoration.

The researchers said that the 3D-printed scaffolds provide a strong structural framework that facilitates the attachment and growth of healthy bone cells. Also, they found that developing bone cells penetrate through the synthetic material, thereby increasing the functionality of the implant.

Although our current work is focused on repairing skull bones, in the near future, we would like to expand this technology for not just craniomaxillofacial defects but also bone regeneration in cases of spinal fusions and other injuries, Kaunas said.

Other contributors to this study include Candice Sears, Eli Mondragon, Zachary Richards, Nick Sears and David Chimene from the Texas A&M Department of Biomedical Engineering; and Eoin McNeill and Carl A. Gregory from the Texas A&M Health Science Center.

This research is funded by the National Institutes of Health and the National Science Foundation.

Here is the original post:
Texas A&M Researchers Use 3D-Printed Biomaterials Laced With Stem Cells To Create Superior Bone Grafts - Texas A&M University Today

Breakthrough discovery could lead to treatment of Fragile X syndrome – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Jun 2 2020

Scientists at the Hotchkiss Brain Institute (HBI), Alberta Children's Hospital Research Institute (ACHRI), and Owerko Centre at UCalgary's Cumming School of Medicine (CSM) have made a breakthrough discovery that could lead to treatment of Fragile X syndrome (FXS), the leading genetic cause of Autism Spectrum Disorder. The study, involving mouse models, shows promise of translating to treatment for people diagnosed with FXS.

FXS causes intellectual disabilities and hyperactive behaviour, usually more commonly seen in males than females. Children and adults with FXS are missing a protein vital to brain development called FMRP. Among other functions, FMRP helps develop synapses between neurons in the brain.

Dr. Raymond W. Turner, PhD, and members of his study team including Drs. Xiaoqin Zhan, PhD, Hadhimulya Asmara, PhD, and Ning Cheng, PhD, made the discovery while studying ion channels in the brain - special proteins that conduct currents through cells, enabling communication within the brain.

If I had to make an analogy, it might be akin to insulin and diabetes. With FXS, individuals are missing this protein - let's try putting it back in. In 30 minutes, the protein distributed throughout the brain, and accomplished what it's supposed to do at the single-cell level."

Dr. Raymond W. Turner, study lead, and professor in the departments of Cell Biology & Anatomy, and Physiology & Pharmacology at the CSM

Unlike injected insulin, which helps someone with diabetes control their blood sugar for a few hours, the FMRP injection helps restore protein levels in the cerebellum and brain for up to one day after the injection. "Hyperactivity was reduced for almost 24 hours," says Zhan, a postdoctoral scholar in the Turner lab. "We did one injection and we tested for it one day later, and three key proteins that are known to be in Fragile X were still at restored normal levels."

In other, unsuccessful attempts to inject mouse models with FMRP to mitigate FXS, scientists used the entire molecule. But Turner and his colleagues used a fragment of FMRP which was able to cross the blood-brain barrier. "It's not a full FMRP molecule at all but rather a fragment with important structural features and functional components that are active in doing things like controlling ion channels or the levels of other proteins," says Cheng, a research associate in the Turner lab.

In the next phase, the researchers will investigate using other parts of the FMRP molecule to mitigate cognitive disorders associated with FXS. "Unlike a lot of drug therapies where you hope you can get your drug to one specific group of cells, FMRP is expressed in just about every cell in the brain, so an all-encompassing wide-based application is what you want," says Turner.

Beyond potential treatments for FXS, the research could help develop treatments to offset behavioural symptoms characteristic of other Autism Spectrum Disorders.

The findings are published in Nature Communications.

Funding for the study was provided by the Canadian Institutes of Health Research (CIHR), Alberta Children's Hospital Foundation through ACHRI, Simons Foundation Autism Research Initiative (SFARI) Explorer grant, and fellowship support from FRAXA and Fragile X Research Foundation of Canada, the HBI and CSM Postdoctoral Fellowship programs.

This technology has a patent through Innovate Calgary, the university's knowledge transfer and business incubator centre, which continues to develop its commercial path through partnership/investment to advance this discovery as a viable treatment for patients.

The Turner lab works on the role of an ion channel complex they discovered that controls multiple functions in the cerebellum that led them to look at the effects of losing FMRP in the knockout mouse model. The reason replacing FMRP was so effective is that it turns out to be part of the very ion channel complex the lab has been studying for 10 years.

Led by the Hotchkiss Brain Institute, Brain and Mental Health is one of six research strategies guiding the University of Calgary toward its Eyes High goals. The strategy provides a unifying direction for brain and mental health research at the university.

Source:

Journal reference:

Zhan, X., et al. (2020) FMRP(1297)-tat restores ion channel and synaptic function in a model of Fragile X syndrome. Nature Communications. doi.org/10.1038/s41467-020-16250-4.

Follow this link:
Breakthrough discovery could lead to treatment of Fragile X syndrome - News-Medical.Net

Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer -…

NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces the appointment of Dr. Wei Li as acting Chief Scientific Officer (CSO), effective June 1, 2020.

During her biotech career, Dr. Li co-founded two companies and built up extensive expertise in all aspects of drug research and development, including preclinical development and pharmacology, clinical development and operations, regulatory affairs, biomarker development and biomanufacturing.

Most recently, Dr. Li was Chief Development Officer at OliX Pharmaceuticals, a leading public South Korean biotech company developing siRNA therapeutics for multiple indications. She also served as Executive Vice President, Product Development at Boston Biomedical, Inc (BBI) from 2007-2018, playing a key role in growing it from a start-up in 2007 to an industry leader in cancer stem cell research, including through the acquisition by Sumitomo Dainippon in 2012. Dr. Li led the development of napabucasin (BBI608), a first-in-class drug selected as one of the worlds top ten cancer drugs in late stage clinical development by Fierce Biotech. Dr. Li started her career at ArQule, a public biotech company developing targeted therapies for hematological malignancies and acquired by Merck &Co in 2019.

Wei Li holds a PhD in Molecular Virology from Georgia State University and completed her Postdoctoral Training at Harvard Medical School.

Dr. Wei Li said: I am thrilled to be joining the great team of scientists and entrepreneurs at Cytovia Therapeutics. NK-cell based therapeutics are at an inflection point. Initial clinical trials have shown promising safety and efficacy. Off-the-shelf manufacturing promises broader and faster patient access. Cytovia Therapeutics has an excellent iPSC CAR-NK platform and a strong pipeline in both hematological and solid tumors. It is tremendously exciting to be involved in this stage of the companys development.

Dr Daniel Teper, co-founder, Chairman and CEO of Cytovia Therapeutics, Inc said: We are delighted to welcome Dr. Wei Li to Cytovia Therapeutics as Chief Scientific Officer. Wei has a stellar track record of bringing innovative oncology drugs from discovery to clinical development. Her operational excellence and entrepreneurial drive will be critical to help bring multiple iPSC CAR NK therapeutics to initial clinical trials starting in 2021.

ABOUT CYTOVIA THERAPEUTICS, INCCytovia Therapeutics is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem and Macromoltek.

Learn more at http://www.cytoviatx.com

Contact for media enquiries at Cytovia Therapeutics, IncSophie BadrVP corporate AffairsSophie.badre@cytoviatx.com1(929) 317 1565

Read more here:
Cytovia Therapeutics, Inc appoints Dr. Wei Li as Chief Scientific Officer to accelerate the development of iPSC CAR-NK Cell Therapy for Cancer -...

NASA-SpaceX launches will boost science research on the space station – wreg.com

When NASA astronaut Dr. Serena Aun-Chancellor arrived on the International Space Station for her six-month stay in June 2018, she was in awe of the vast array of science experiments on board. Before they launch, astronauts are only trained on about 20% of the science they see on the station.

I was stunned, in a good way, at the high quality of the science, she told CNN. During her time on the space station, Aun-Chancellor worked on hundreds of experiments across a variety of sciences, includingbiology, biotechnology, physical science and Earth science.

As a practicing physician, as well as clinical associate professor of medicine at Louisiana State University Health New Orleans School of Medicines branch campus in Baton Rouge, she could see the real-world applications of the medical experiments on the station.

Some of these included researching a protein that contributes toParkinsons disease, improving age-related macular degeneration and theAngiex Cancer Therapy study. The Angiex research was used to test a safer, more effective treatment targeting tumor cells and blood vessels.

I could picture a patient with each of these experiments, she said. Its tremendously enlightening and heartwarming because a good portion of the life sciences research on the space station is for people on Earth, not for astronauts who will go to Mars.

She and her fellow astronauts also installed a new Life Sciences Glovebox suited for biological research, which also allows two astronauts to simultaneously interact with the experiment inside.

Aun-Chancellor said that astronauts tend to have an eight-hour workday on the space station, and much of that is dominated by science experiments. She could spend as much as four hours on one experiment alone while the other astronauts worked on different experiments, she said.

From the time construction began on the space station in 1998 until now, nearly 3,000 different experiments have been conducted on the station.

More than 4,000 scientists have had their work represented on the station, with those scientists and research stemming from 108 countries globally, according to NASA.

Now, NASAs Commercial Crew program can expand the amount of astronauts on the space station which means that more science, and even new types of experiments, can happen in the unique microgravity environment.

SpaceXs Crew Dragon spacecraft launched Saturday atop a SpaceX Falcon 9 rocket from Cape Canaveral carrying NASA astronauts Robert Behnken and Douglas Hurley. Its the first time in history that a commercial aerospace company has carried humans into Earths orbit.

The United States hasnt launched its own astronauts into space since the Space Shuttle Program ended in 2011. Since then, NASAs astronauts have had to travel to Russia and train on the countrys Soyuz spacecraft.

This mission, called Demo-2, is just the beginning of launching astronauts from American soil for stays of varying lengths on the space station. That means more scientific experiments in space that can help us out on Earth, as well as astronauts who may be going to the moon or eventually, to Mars.

The majority of the science that has occurred on the space station has taken place over the last 10 years the 10 years prior were spent building and outfitting it to be a laboratory orbiting the Earth.

While the astronauts also work on maintaining the space station, exercising, working with robotics and preparing for and executing spacewalks outside the station, the majority of each day is spent on science, Aun-Chancellor said.

National labs on Earth tend to focus on one kind of science.

We focus on what we can offer that is unique, which is withholding gravity as a variable, said NASA astronaut Christina Koch, who returned to Earth in February. The space environment affords a wide spectrum of discovery.

One of the many experiments Koch worked on during her record-breaking stay of 328 days on the space station involved protein crystal growth. Understanding those proteins could lead to pharmaceuticals that can fight cancer.

Some of these crystallized proteins cant form on Earth, while others dont form as well. However, they grow well in the stationsmicrogravity environment, often larger and more well-ordered than crystals grown on Earth, which allows them to be studied more in depth. Crystals grown on the space station have avariety of applicationsacross different sciences and technologies.

Two decades of research on the space station has allowed scientists to realize the potential of eliminating gravity as a factor from their experiments.

For example, 3D structures form better in the absence of gravity because Earths gravity can pull on those structures and flatten them out, said Jennifer Buchli, the space stations deputy chief scientist. This includes 3D bioprinting on the space station. In recent years, the US National Institutes of Health has partnered with the ISS National Lab to flytissue chip experimentson the station.

Theyre physiological systems on something the size of a USB stick that can be used to test drug efficiency and model patients, Buchli said.

Other experiments in recent years include investigations about growing plants in space, slowing down atoms so they can be studied in theCold Atom Lab, testingbuilding supplies for the moonand studying howfire reacts in space.

The experiments vary in how much interaction they require from the crew on the space station. Some are self sufficient, only requiring occasional interaction by an astronaut, while others are much more hands on.

Science is a time-intensive task and the crew members are our hands, eyes and ears to complete a lot of science, Buchli said.

But the basic fact remains that more people on the space station means more science can be achieved because the amount of crew has been a limiting factor. With Commercial Crew, four NASA astronauts can go up at one time, rather than the three astronauts and Russian cosmonauts that can fit in the Soyuz.

Commercial Crew can also launch more frequently and bring the woman and manpower to get it done, Aun-Chancellor said. The science is up there, its just waiting for us to complete it.

When we have four US crew members, we can double the number of hours devoted to science each week and accomplish science that wasnt previously feasible in a crew day, Buchli said. That means more than 100 hours per week can be spent on science in the future.

This means that astronauts could either double up on experiments by working together or split into shift teams where they stagger when the astronauts are awake and asleep, so crews could hand off an experiment that requires 13 hours rather than six especially an issue in life sciences, cell biology and rodent research.

Commercial Crew also expands the flexibility for transporting things to and from the station, she said. The Soyuz launches occur about every six months, while Commercial Crew vehicles will allow them to launch and land with varying lengths of time on station.

That means more live refrigerated samples and cells grown and tested on the space station can be returned exactly when they need to be for scientists to study them on the ground and detail how they changed in space.

More repeats of science experiments can also occur. If a research team is granted a second flight of an experiment, they can repeat it to gather additional data.

You dont just run an experiment once on the ground, Buchli said. You refine things as you go. This is exciting because the space station is starting to function more like a ground lab, allowing repetition and the chance to optimize and tweak science.

More frequent flights means that astronauts can also experience missions of shorter duration, which can fill a crucial gap when it comes to monitoring astronaut health. These missions would last between two to three months.

Current astronaut health data has been taken from those who went up on shuttle flights, which lasted between 10 and 18 days, average space station missions lasting six months, and a few extended missions that were closer to a year, like astronautsScott Kelly,Peggy WhitsonandChristina Koch.

It also means that extended stays are possible to prepare for the long flight to Mars.

This will allow NASA and their Human Research Program to better study the effects of space on human health and develop countermeasures to mitigate them especially as they prepare to send astronauts back to the moon and eventually on to Mars.

Non-NASA research is managed by the ISS National Laboratory, which utilizes the space stations unique microgravity environment to send up experiments from commercial businesses, academic institutions and government agencies that can benefit Earth.

During his time with the ISS National Lab, Chief Operating Officer Ken Shields has enjoyed watching the variety of both experiments and their investigators as they push the envelope of existing technologies.

Were breaking barriers in the world of research development and technology, Shields told CNN. And were entering a new era in space research and development.

The space station is like a test kitchen to experiment and prove out concepts, he said.

A small scale of success on the space station may mean that an investigation could later be moved to another low-Earth orbit vehicle. Multiple commercial research and development partners have been running a portion of their business in space through installations on the space station, and the technology advancements gained in space can help Earth.

The International Space Station is an unmatched tool of inspiration and engagement, he said.

Some of the science conducted on the space station actually stems from student experiments. Seeing their research happen in space will inspire future generations, he said. Going forward, the ISS National Lab wants to make sure that all students, especially those in underrepresented demographics, have the opportunity.

The last 20 years saw the building and completion of the space station, as well as research and development of science and technology experiments in space to provide people with applicable innovationson Earth.

Shields saw nothing but opportunities ahead.

Im hopeful that we can continue to enable and facilitate more groundbreaking efforts that have importance not only to individual academic institutions or companies, but are more broadly felt to create solutions to problems that are important to us as a nation, Shields said.

See the original post:
NASA-SpaceX launches will boost science research on the space station - wreg.com

Ervaxx rebrands as Enara Bio to reflect a broader emphasis on the discovery and development of novel TCR-based cancer immunotherapies – PharmiWeb.com

Oxford and London, UK 3rd June 2020. Enara Bio (formerly Ervaxx), a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen platforms to deliver targeted cancer immunotherapies, announces its new name Enara Bio Limited. This new name reflects the companys expanded product discovery and development strategy beyond its initial focus on endogenous retroviral (ERV) antigens for the development of cancer vaccines (hence Ervaxx).

Enara is derived from an Arabic word that means illumination, enlightenment and bringing light into darkness. The company believes this new name more closely illustrates Enara Bios mission as a science-led organization exploring the genomic dark matter as a source of novel cancer-specific T-cell antigens. The rebrand also recognizes the companys new TCR research capabilities, including programs that could enable immune recognition of a broad range of tumor cell types in an HLA-independent fashion, and thus offer broadly applicable T-cell therapies. By building discovery efforts on both sides of the T-cell/cancer-cell interface (the immune synapse), Enara Bio is building a pipeline of cancer immunotherapies for broad patient populations.

The company was founded as Ervaxx Ltd. in late 2016 with an initial focus on the development of therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV) DNA sequences. Since then, and based on breakthrough science coming from both internally-generated and in-licensed insights, Enara Bio has broadened its horizons to include TCR-based immunotherapies targeting an extended cancer-associated antigenic repertoire derived from the entire genomic dark matter, termed Dark Antigens.

To accelerate this evolution, Enara Bio in-licensed patents covering T cells and TCRs reactive to cancer-specific antigens and ligands from Cardiff University in January 2020. These exciting new technologies, while early research-stage, present compelling opportunities to develop immunotherapies with the potential to address a broad range of tumor types independent of the patients genetic background.

Kevin Pojasek, President and CEO of Enara Bio commented:

Our new name Enara Bio reflects the progression of our strategy and capabilities to align more broadly with our purpose of delivering impactful immunotherapies to all cancer patients. Our ground-breaking work in identifying and characterizing Dark Antigens is now joined by other exciting new programs focused on pan-cancer, pan-HLA targets, which greatly expand our opportunities for the development of novel immunotherapies with broad utility across patients with diverse cancers. While we continue to press ahead with these exciting programs internally, we are increasingly seeking partnerships to advance the full diversity of our science and product opportunities.

***

About Enara Bio

Enara Bio (formerly Ervaxx) is a science-led company targeting the T-cell/cancer-cell interface (the immune synapse) to develop new targeted cancer immunotherapies designed to treat a broad patient population.

Enara Bio is exploring the hidden depths of cancer and T-cell biology to discover and characterize novel immunotherapy targets, such as Dark Antigens and MR1-presented ligands. We are pioneering approaches to exploit these targets with TCR-directed T-cell immunotherapy and therapeutic vaccines.

To achieve our mission, we are leveraging our differentiated Dark Antigen and TCR discovery platforms that integrate bioinformatics, immunopeptidomics, metabolomics and immunology in our Oxford, UK-based research lab.

Enara Bio is backed by leading life science investors, including SV Health Investors. We have partnerships with world-class academic institutions, including the Francis Crick Institute, Cardiff University, Johns Hopkins School of Medicine and the University of Oxford, to help drive the leading edge of these new areas of science.

For more information visit: http://www.enarabio.com

Visit link:
Ervaxx rebrands as Enara Bio to reflect a broader emphasis on the discovery and development of novel TCR-based cancer immunotherapies - PharmiWeb.com